Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

FDA Approves Medical Device For Monthly Injection Of PCSK9 Inhibitor



High levels of LDL cholesterol in the blood has been associated with a higher risk of cardiovascular disease.

Tweetables from this article:

Tweet: Repatha is a monoclonal antibody PCSK9 inhibitor http://ctt.ec/G26yL+Repatha is a monoclonal antibody PCSK9 inhibitor.

Tweet: High levels of LDL cholesterol associated with cardiovascular disease http://ctt.ec/dfqbS+High levels of LDL cholesterol associated with cardiovascular disease.

Share this!

July 12, 2016 | by Sarah Massey, M.Sc.

The US Food and Drug Administration (FDA) has approved a new monthly, single dose medical device - called Pushtronex - for the infusion of the LDL cholesterol-lowering drug, Repatha. Marketed by Amgen, Repatha is a monoclonal antibody belonging to the PCSK9 inhibitor class of drugs.

The Pushtronex hands-free medical device consists of a pre-filled cartridge containing 420 mg of Repatha. Despite the availability of other PCSK9 inhibitors, Amgen is the first company to offer the biologic as a once-monthly treatment.

“The Pushtronex system exemplifies Amgen's continued innovation and commitment to patients,” said Dr. Sean E. Harper, executive vice president of Research and Development at Amgen. “Repatha is the only PCSK9 inhibitor with an approved monthly dose, and now the only one with a monthly single-dose administration. The FDA approval of the Pushtronex system offers another delivery option to patients who need the additional LDL cholesterol lowering that Repatha can provide.”

Repatha is approved in the US to treat LDL cholesterol-associated conditions, including heterozygous familial hypercholesterolemia (HeFH), clinical atherosclerotic cardiovascular disease (ASCVD) and homozygous familial hypercholesterolemia (HoFH). In some indications, it is used in combination with other cholesterol-lowering therapies, such as statins, and in conjunction with changes in diet.

Based on SmartDose Technology, Amgen developed the single-use medical device in collaboration with West Pharmaceutical Services. By offering an additional dosing option, patients are able to perform moderate physical tasks such as walking, while receiving their dose of Repatha subcutaneously.

According to Amgen, the U.S. Wholesale Acquisition Cost (WAC) of Repatha is $14,100 annually, however the company anticipates the patient and payer costs to be significantly lower. Amgen expects the Pushtronex system will be available to US patients as early as August.

High levels of LDL cholesterol in the blood has been associated with a higher risk of cardiovascular disease. Approximately 11 million people in the US have ASCVD and/or familial hypercholesterolemia (FH), which is not adequately controlled using traditional statin drugs or other cholesterol-lowering treatments alone.

Amgen’s Repatha is currently approved in 43 countries, including major markets in the US, Japan and Canada. While applications in other countries are pending, the drug is also available in all 28 member states in the EU.

Keywords: FDA, Medical Device, PCSK9 Inhibitor


Share this with your colleagues!

Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News

FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News

One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


Top 5 Most Impactful Tweets in Life Sciences During the Last Week


EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider

Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology

Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn

eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials

Copyright © 2016-2017 Honeycomb Worldwide Inc.